Demis Hassabis-led Isomorphic Labs in Advanced Talks for $40-50 Billion Valuation

Alphabet-backed AI drug discovery startup Isomorphic Labs is in preliminary funding discussions targeting a valuation of $40 billion to $50 billion, just five months after securing $2.1 billion in Series B funding, according to reports. The London-based company, led by CEO and DeepMind Chairman Demis Hassabis, has built IsoDDE (Isomorphic Labs Drug Design Engine), a unified AI platform for designing therapeutic molecules across multiple disease areas and drug modalities.